Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
861 to 880 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| COVID-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high-precision disease management. | J Cell Mol Med | 2023 | 36537107 | PubTator, text mining | PubMed |
| Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4+ T cell reservoir. | Nat Immunol | 2023 | 36536105 | PubTator, text mining | PubMed |
| Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia. | Int J Cancer | 2023 | 36533670 | PubTator, text mining | PubMed |
| The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. | Adv Sci (Weinh) | 2023 | 36529697 | PubTator, text mining | PubMed |
| Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas. | Blood Adv | 2023 | 36521030 | PubTator, text mining | PubMed |
| Progress of radiological‑pathological workflows in the differential diagnosis between primary central nervous system lymphoma and high‑grade glioma (Review). | Oncol Rep | 2023 | 36484403 | PubTator, text mining | PubMed |
| CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma. | Cancer Med | 2023 | 36478416 | PubTator, text mining | PubMed |
| Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. | Blood Adv | 2023 | 36469024 | PubTator, text mining | PubMed |
| A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. | Leukemia | 2023 | 36460764 | PubTator, text mining | PubMed |
| Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation. | Virchows Arch | 2023 | 36454275 | PubTator, text mining | PubMed |
| Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. | Leukemia | 2023 | 36435884 | PubTator, text mining | PubMed |
| Plasma cell neoplasms and related entities-evolution in diagnosis and classification. | Virchows Arch | 2023 | 36414803 | PubTator, text mining | PubMed |
| Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients. | Cancer Rep (Hoboken) | 2023 | 36411516 | PubTator, text mining | PubMed |
| Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. | Cancer | 2023 | 36408673 | PubTator, text mining | PubMed |
| Single-cell RNA-seq analysis to identify potential biomarkers for diagnosis, and prognosis of non-small cell lung cancer by using comprehensive bioinformatics approaches. | Transl Oncol | 2023 | 36401966 | PubTator, text mining | PubMed |
| Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey. | Ann Hematol | 2023 | 36401621 | PubTator, text mining | PubMed |
| Prevention and management of secondary central nervous system lymphoma. | Haematologica | 2023 | 36384246 | PubTator, text mining | PubMed |
| Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate. | Mol Pharm | 2023 | 36377696 | PubTator, text mining | PubMed |
| Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. | Cancer Commun (Lond) | 2023 | 36357174 | PubTator, text mining | PubMed |
| Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma. | Leukemia | 2023 | 36352191 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=44